`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS
`USA, INC.,
`
`
`Plaintiffs,
`
`
`v.
`
`ELI LILLY AND COMPANY,
`
`
`Defendant.
`
`
`
`
`Civil Action No.
`1:18-cv-12029-ADB
`
`
`
`
`
`
`STIPULATION AND [PROPOSED] ORDER REGARDING ASSERTED CLAIMS
`
`Plaintiffs Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.
`
`(collectively, “Teva”) and Defendant Eli Lilly and Company (“Lilly”) (all together, the “Parties”)
`
`have agreed to enter into this stipulation to streamline the issues in dispute in this matter, subject
`
`to the approval of the Court;
`
`WHEREAS, Teva has asserted claims 17, 18, 19, 20, 21, 24, 27, and 30 of U.S. Patent
`
`No. 8,586,045 (“the ’045 patent”); claims 1, 4, 5, 6, 15, and 17 of U.S. Patent No. 9,884,907 (“the
`
`’907 patent”); and claims 1, 4, 5, 6, 15, and 17 of U.S. Patent No. 9,884,908 (“the ’908 patent”)
`
`against Lilly; and
`
`WHEREAS, on October 3, 2022, the Court entered a Memorandum and Order On Cross-
`
`Motions for Summary Judgment (ECF No. 513), granting Lilly’s motion for partial summary
`
`judgment of non-infringement with respect to claims 18 and 21 of the ’045 patent;1
`
`
`1 Teva reserves all appellate rights with respect to the October 3, 2022 summary judgment decision,
`ECF No 513, and claims 18 and 21 of the ʼ045 patent.
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 2 of 6
`
`WHEREAS, in view of the Court’s order granting partial summary judgment of non-
`
`infringement with respect to claims 18 and 21 of the ’045 patent, Lilly will agree to dismiss its
`
`counterclaims of invalidity with respect to claims 18 and 21 of the ’045 patent without prejudice;
`
`and
`
`WHEREAS, the Parties seek to further reduce the number of claims and defenses to
`
`streamline the issues for trial, and accordingly hereby agree to dismiss certain claims and certain
`
`corresponding counterclaims and defenses.
`
`NOW THEREFORE, IT IS HEREBY STIPULATED AND AGREED, by and between
`
`the Parties hereto, and subject to the approval of the Court, as follows:
`
`1.
`
`Lilly stipulates that it voluntarily dismisses its counterclaims of invalidity
`
`pertaining to claims 18 and 21 of the ’045 patent without prejudice.
`
`2.
`
`Teva stipulates that it voluntarily dismisses its claims of infringement against Lilly
`
`of claims 17, 19, 20, 24, and 27 of the ʼ045 patent; claims 1, 4, 15, and 17 of the ʼ907 patent; and
`
`claims 1, 4, 15, and 17 of the ’908 patent pertaining to Lilly’s Emgality® (galcanezumab-gnlm)
`
`product with prejudice pursuant to Fed. R. Civ. P. 41(a)(2).
`
`3.
`
`Lilly stipulates that it voluntarily dismisses its defenses and counterclaims of
`
`invalidity and non-infringement pertaining to claims 17, 19, 20, 24, and 27 of the ʼ045 patent;
`
`claims 1, 4, 15, and 17 of the ʼ907 patent; and claims 1, 4, 15, and 17 of the ’908 patent with
`
`prejudice pursuant to Fed. R. Civ. P. 41(a)(2).2
`
`4.
`
`The Parties stipulate that they will continue to assert their respective claims (see
`
`ECF No. 1, Counts I, VI, VII, X, XV, and XVI), counterclaims (see ECF No. 277, Counterclaim
`
`
`2 For the avoidance of doubt, Lilly does not voluntarily dismiss its affirmative defenses and
`counterclaims of unclean hands and inequitable conduct, which apply to the entire patents, not
`individual patent claims.
`
`2
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 3 of 6
`
`Counts I, II, XI–XIV, and XIX–XXI), and defenses (see ECF No. 277, Defenses 1, 2, 11–14, 20-
`
`25) with respect to only claims 30 of the ’045 patent; claims 5 and 6 of the ’907 patent; and claims
`
`5 and 6 of the ’908 patent.
`
`5.
`
`Without prejudice to any other claim or defense Lilly has in this action, including
`
`as to invalidity, unenforceability, no indirect infringement, and no willful infringement, Lilly
`
`stipulates and agrees that the use of Lilly’s Emgality® (galcanezumab-gnlm) product (described in
`
`BLA No. 761063) for the preventive treatment of migraine in the United States directly infringes
`
`under 35 U.S.C. § 271(a) claim 30 of the ’045 patent; claims 5 and 6 of the ’907 patent; and claims
`
`5 and 6 of the ’908 patent, under the Court’s Memorandum and Order on Claim Construction (ECF
`
`No. 101).3
`
`6.
`
`Without prejudice to any other claim or defense Lilly has in this action, including
`
`as to invalidity, unenforceability, no indirect infringement, and no willful infringement, Lilly
`
`stipulates and agrees that the use of Lilly’s Emgality® (galcanezumab-gnlm) product (described in
`
`BLA No. 761063) for the treatment of episodic cluster headache directly infringes under 35 U.S.C.
`
`§ 271(a) claim 30 of the ’045 patent; claim 5 of the ’907 patent; and claim 5 of the ’908 patent,
`
`under the Court’s Memorandum and Order on Claim Construction (ECF No. 101).
`
`IT IS SO ORDERED
`
`Dated:
`
`10/17/22
`
`Hon. Allison D. Burroughs
`United States District Judge
`
`3 For the avoidance of doubt, Lilly reserves all appellate rights with respect to the Memorandum
`and Order on Claim Construction (ECF No. 101).
`
`3
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 4 of 6
`
`Dated: October 17, 2022
`
`/s/ Elaine Herrmann Blais
`Douglas J. Kline (BBO# 556680)
`Elaine Herrmann Blais (BBO# 656142)
`Robert Frederickson III (BBO# 670111)
`Molly Grammel (BBO# 688439)
`Kevin P. Martin (BBO# 655222)
`Joshua S. Weinger (BBO# 690814)
`Alexandra Lu (BBO# 691114)
`Eric T. Romeo (BBO# 691591)
`Kathleen A. McGuinness (BBO# 693760)
`Tara R. Thigpen (BBO# 707508)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`Tel.: (617) 570-1000
`Fax: (617) 523-1231
`dkline@goodwinlaw.com
`eblais@goodwinlaw.com
`rfrederickson@goodwinlaw.com
`mgrammel@goodwinlaw.com
`kmartin@goodwinlaw.com
`jweinger@goodwinlaw.com
`alu@goodwinlaw.com
`eromeo@goodwinlaw.com
`kmcguinness@goodwinlaw.com
`tthigpen@goodwinlaw.com
`
`Natasha E. Daughtrey (pro hac vice)
`Sean M. Anderson (pro hac vice)
`GOODWIN PROCTER LLP
`601 S. Figueroa St.
`Los Angeles, CA 90017
`Tel.: (213) 426-2500
`Fax: (213) 623-1673
`ndaughtrey@goodwinlaw.com
`sanderson@goodwinlaw.com
`
`
`Respectfully submitted,
`
`s/ Andrea L. Martin (with permission)
`Andrea L. Martin (BBO 666117)
`BURNS & LEVINSON LLP
`125 High Street
`Boston, MA 02110-1624
`(617) 345-3000
`amartin@burnslev.com
`
`Charles E. Lipsey
`Ryan O’Quinn
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`1875 Explorer Street
`Suite 800
`Reston, VA 20190-6023
`Charles.Lipsey@finnegan.com
`Oquinnr@finnegan.com
`
`Emily R. Gabranski
`Marta Garcia Daneshvar
`Lulu Wang
`Li Zhang
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`2 Seaport Lane
`Boston, MA 02210-2001
`Emily.Gabranski@finnegan.com
`Marta.Garcia@finnegan.com
`Lulu.Wang@finnegan.com
`Li.Zhang@finnegan.com
`
`William B. Raich
`Denise Main
`Danielle A. Duszczyszyn
`Pier D. DeRoo
`Matthew J. Luneack
`Yoonjin Lee
`Sydney Kestle
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`William.Raich@finnegan.com
`Denise.Main@finnegan.com
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 5 of 6
`
`Madeline R. DiLascia (pro hac vice)
`GOODWIN PROCTER LLP
`1900 N Street N.W.
`Washington, D.C. 20036
`Tel.: (202) 346-4000
`Fax: (202) 204-7250
`mdilascia@goodwinlaw.com
`
`Attorneys for Plaintiffs
`
`
`
`
`
`
`Danielle.Duszczyszyn@finnegan.com
`Pier.Deroo@finnegan.com
`Matthew.Luneack@finnegan.com
`Yoonjin.Lee@finnegan.com
`Sydney.Kestle@finnegan.com
`
`Attorneys for Defendant Eli Lilly and
`Company
`
`
`
`
`
`Case 1:18-cv-12029-ADB Document 531 Filed 10/17/22 Page 6 of 6
`
`CERTIFICATE OF SERVICE
`
`I, Elaine Herrmann Blais, hereby certify that a copy of the foregoing document, filed
`
`through the CM/ECF system, will be sent electronically to the registered participants as identified
`
`on the Notice of Electronic Filing (“NEF”) and paper copies shall be served by first class mail
`
`postage prepaid on all counsel of record who are not served through the CM/ECF system on
`
`October 17, 2022.
`
`
`
`
`
`/s/ Elaine Herrmann Blais
`Elaine Herrmann Blais (BBO# 656142)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`(617) 570-1000
`eblais@goodwinlaw.com
`
`
`
`